New indications NexGard, NexGard SPECTRA and Broadline

New therapeutic indications for NexGard ®, NexGard SPECTRA® and Broadline® approved by EMAThe marketing authorization variations were validated by the EU Commission decision1 and subsequently approved by EMANew indications were received as follows:NexGard ® and NexGard SPECTRA® for the treatment against Ixodes hexagonus tickNexGard SPECTRA ® for the prevention of establishment of thelaziosisBroadline ® for the treatment of adult and larval stages (L4) of Ancylostoma ceylanicum

Source: Boehringer Ingelheim Corporate News - September 27, 2019 Category: Research Source Type: news